CD147 supports paclitaxel resistance via interacting with RanBP1.

Gang Nan, Shu-Hua Zhao, Ting Wang, Dong Chao, Ruo-Fei Tian, Wen-Jing Wang, Xin Fu, Peng Lin, Ting Guo, Bin Wang, Xiu-Xuan Sun, Xi Chen, Zhi-Nan Chen, Shi-Jie Wang, Hong-Yong Cui

Oncogene 2022 Feb

filter terms:

Though the great success of paclitaxel, the variable response of patients to the drug limits its clinical utility and the precise mechanisms underlying the variable response to paclitaxel remain largely unknown. This study aims to verify the role and the underlying mechanisms of CD147 in paclitaxel resistance. Immunostaining was used to analyze human non-small-cell lung cancer (NSCLC) and ovarian cancer tissues. RNA-sequencing was used to identify downstream effectors. Annexin V-FITC/propidium iodide and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were used to detect apoptosis. Co-immunoprecipitation (Co-IP), fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR) were performed to determine protein interactions. Fluorescence recovery after photobleaching (FRAP) was performed to measure the speed of microtubule turnover. Xenograft tumor model was established to evaluate sensitivity of cancer cells to paclitaxel in vivo. In vitro and in vivo assays showed that silencing CD147 sensitized the cancer cells to paclitaxel treatment. CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status. Truncation analysis showed that the intracellular domain of CD147 (CD147ICD) was indispensable for CD147-regulated sensitivity to paclitaxel. Via screening the interacting proteins of CD147ICD, Ran binding protein 1 (RanBP1) was identified to interact with CD147ICD via its C-terminal tail. Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment. These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant. © 2021. The Author(s).

Citation

Gang Nan, Shu-Hua Zhao, Ting Wang, Dong Chao, Ruo-Fei Tian, Wen-Jing Wang, Xin Fu, Peng Lin, Ting Guo, Bin Wang, Xiu-Xuan Sun, Xi Chen, Zhi-Nan Chen, Shi-Jie Wang, Hong-Yong Cui. CD147 supports paclitaxel resistance via interacting with RanBP1. Oncogene. 2022 Feb;41(7):983-996